CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 35 enrolled
Drug / intervention
stereotactic body radiation therapy +2 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01664130
NCT01664130N/ACompleted
CompareCT.gov

High-Dose Stereotactic Body Radiation Therapy in Treating Patients With Low-, Intermediate-, or High-Risk Localized Prostate Cancer

Case Comprehensive Cancer Center·interventional·Posted Aug 14, 2012·Updated May 21, 2020

In Brief

A clinical study evaluating stereotactic body radiation therapy, quality-of-life assessment, and 1 other intervention for Adenocarcinoma of the Prostate and 5 related conditions. Completed, enrolled 35 participants across 1 site.

Detailed Summary

This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer. SBRT may be able to send x-rays directly to the tumor and cause less damage to normal tissue

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedAug 14, 2012
Enrollment StartJul 1, 2012
Primary CompletionJan 12, 2017
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 13.9 years ago

Interventions

stereotactic body radiation therapyradiation

Undergo SBRT

quality-of-life assessmentprocedure

Ancillary studies

laboratory biomarker analysisother

Correlative studies